Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Shares Outstanding (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Shares Outstanding for 6 consecutive years, with $60.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 2.23% to $60.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $60.4 million through Dec 2025, up 2.23% year-over-year, with the annual reading at $60.4 million for FY2025, 2.23% up from the prior year.
  • Shares Outstanding for Q4 2025 was $60.4 million at Janux Therapeutics, roughly flat from $60.1 million in the prior quarter.
  • The five-year high for Shares Outstanding was $60.4 million in Q4 2025, with the low at $1.2 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $42.3 million, with a median of $41.8 million recorded in 2023.
  • The sharpest move saw Shares Outstanding skyrocketed 4146.43% in 2021, then rose 0.88% in 2023.
  • Over 5 years, Shares Outstanding stood at $41.2 million in 2021, then grew by 0.9% to $41.6 million in 2022, then rose by 11.14% to $46.3 million in 2023, then rose by 27.7% to $59.1 million in 2024, then increased by 2.23% to $60.4 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $60.4 million, $60.1 million, and $59.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.